Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion

Corroborated by 7 sources from 7 publishers

globalhealth7h ago

TL;DR

23, 2025. Antranik Tavitian | Reuters Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at about $6.3 billion to expand into treatments for sleep-wake disorders. The acquisition adds Centessa’s sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly’s neuroscience business.

Sources